Key Takeaways
- Consolidation drove a 191% revenue jump: FY25 consolidated revenue surged YoY, but this was overwhelmingly a mechanical effect of full-period US subsidiary consolidation, not organic acceleration.
- The US subsidiary dilutes margins: The US business runs a high-volume, low-margin RLD distribution model, so the consolidated sales growth far outpaces bottom-line growth.
- B2C branding is the margin story: Management is pivoting from B2B distribution to own-brand B2C, targeting a jump from 10–15% of business to 25–30% by year-end, which it expects will drive a strong improvement in gross margins.
- Weight-loss drugs are a near-term catalyst: Filings for Semaglutide and Mounjaro (injections and tablets) have commenced, with first revenues from non-patent markets expected in H2 FY26.
- What to watch next quarter: Whether the B2C share actually climbs toward the 25–30% target, the pace of gross margin expansion, and any concrete revenue contribution from the weight-loss portfolio.
The Consolidation Effect: Revenue vs. Margins
- 191% YoY revenue growth was driven by the full-period consolidation of the US subsidiary in FY25, versus only partial consolidation in the prior year.
- Bottom-line growth lags top-line growth because the US subsidiary operates a high-volume, low-margin RLD distribution model focused on absolute margins through volume. Consolidating three subsidiaries with the holding company means the growth in sales is not proportionate to growth in margins.
- Sustainable, not exorbitant, growth ahead: Management explicitly stated there will not be the kind of exorbitant growth seen previously, which was due to consolidation, and that future growth will be sustainable on the current revenue base.
B2C Branding: The Margin Expansion Engine
- Current B2C share is 10–15% of the business; management targets at least 25–30% by the end of this year.
- More own-brand launches in the B2C model are expected to drive margin expansion over the next year or so, with strong improvement in gross margins anticipated in H1, H2 and coming years as the B2C share grows.
- 570 B2C products are currently in the portfolio; the company is looking at around 250 B2C products within a year.
- Branded generics pricing resilience: In branded generics, price erosion does not happen the way it does in typical generic markets, so the company expects to maintain healthy profit margins on these products.
Swapnil Shah: "So as you know, branded generics, the price erosion doesn't happen the way it happens on a typical generic that exists in this market. So of course, there is going to be little bit on price pressure, but we feel we are going to be able to maintain healthy profit margins on these products."
Weight-Loss Portfolio: The Next Catalyst
- Semaglutide and Mounjaro filings have commenced across all strengths, for both injections (PFS) and tablets. These products were already in the portfolio and have been developed; filing is now underway.
- Weight-loss is a focused category going forward: Semaglutide, Mounjaro, Rybelsus (semaglutide oral solid) and other molecules will be pursued across all markets where Remus operates.
- First revenues expected in H2 FY26: Sales and revenues from products in markets without patent issues will come "pretty soon, probably H2."
Geographic Expansion: Latin America and Beyond
- Latin America is the powerhouse: The first operational subsidiary in Bolivia (Relius) has launched 15+ products across private market, pharmacy chains, private hospitals and government institutions, supported by targeted programs for gynecology, general practitioners and hematologists.
- Own-brand push in new LatAm markets: The company initiated its own brand and marketing process in Chile, Peru, Dominican Republic and El Salvador.
- New market entries underway: Product registration has begun in Bosnia, Kosovo, Mexico, Tanzania, Azerbaijan, Mauritius, Bhutan and Cambodia.
- Singapore branch office: Remus decided to open a branch office in Singapore, dropping an earlier plan for Dubai, citing Singapore's flexibility for doing business and its strategic value for an international company.
- Export footprint spans 40+ countries, with more than 95% of exports coming from advanced and niche formulations (tablets, capsules, injections, inhalers, soft gels, oral suspensions).
Arpit Shah: "What sets us apart is our ability to enter markets with new products in a record time so as to take the first mover advantage in short span of time."
Business Model & Competitive Positioning
- Pure marketing and distribution play: Remus is purely marketing, distribution, branding, B2C and B2B; 90–95% of products are outsourced from CMOs with no in-house manufacturing.
- No overlap with Senores: Remus operates only in emerging markets (rest of world), while Senores has major business in regulated markets. There is no overlap or conflict between the two companies.
- R&D at 2–3% of revenue is incurred because Remus registers multiple products in multiple countries; each registration requires a certain level of development to ensure approval by the country's ministry of health.
- 170 new trademarks and product registrations were filed, with 35 secured and approved; over 10 off-patent pharmaceutical products were commercialized in H2 FY25.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| B2C share expansion | B2C to reach at least 25–30% of business (from 10–15% currently) | By end of this year (FY26) |
| B2C product count | Around 250 B2C products in portfolio (from 570 currently) | Within a year |
| Gross margin improvement | Strong improvement anticipated as B2C share grows | H1, H2 and coming years |
| Semaglutide/Mounjaro revenue | First sales from non-patent markets | H2 FY26 |
| Growth character | Sustainable growth on current revenue base; no exorbitant growth like the consolidation-driven spike | Ongoing |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| H2 FY25 consolidated revenue | ₹347.75 cr, +88% YoY; periods not comparable due to partial consolidation of US subsidiary in prior period |
| H2 FY25 consolidated EBITDA | ₹27.15 cr, +29% YoY |
| H2 FY25 consolidated net profit before minority interest | ₹20.57 cr, +10% YoY |
| H2 FY25 consolidated net profit after minority interest (Remus share) | ₹16.01 cr |
| FY25 consolidated revenue | ₹620.36 cr, +191% YoY; full period for US subsidiary vs partial consolidation in prior period |
| FY25 consolidated EBITDA | ₹50.67 cr, +59% YoY |
| FY25 consolidated net profit before minority interest | ₹38.42 cr, +58% YoY |
| FY25 consolidated net profit allocated to Remus | ₹29.07 cr |
| H2 FY25 standalone revenue | ₹41.49 cr, +14% YoY |
| H2 FY25 standalone EBITDA | ₹15.70 cr, +15% YoY |
| H2 FY25 standalone net profit | ₹10.71 cr, +22% YoY |
| FY25 standalone revenue | ₹79.16 cr, +23% YoY |
| FY25 standalone EBITDA | ₹28.88 cr, +26% YoY |
| FY25 standalone net profit | ₹19.90 cr, +18% YoY |
| R&D spend | 2% to 3% of turnover, expected to remain at this level |
| B2C share of business | 10% to 15% currently; expected to reach at least 25% to 30% by end of year |
| B2C gross margin | 65% to 70% (per an analyst's math) |
| Overall gross margin guidance | 40% (per an analyst's math) |
| B2C products currently | 570 |
| B2C product target within a year | ~250 additional products |
| New trademarks and product registrations filed in H2 FY25 | 170 filed, 35 secured and approved |
| Products commercialized in H2 FY25 | Over 10 off-patent pharmaceutical products |
| Products launched by Bolivia subsidiary (Relius) | More than 15 across private market, pharmacy chains, hospitals, and government institutions |
| Brand awareness conference attendance | More than 55 doctors and pharmacy representatives |
| Countries of export presence | More than 40 countries |
| Share of exports from advanced and niche formulations | More than 95% |